Notice of Intent to Award Multiple Blanket Purchase Agreements for Sterilely Compounded Pharmaceuticals via 503B Compounding Pharmacies for Gallup Indian Medical Center NOI-GSUT2-20260003
Summary
AI-generated · Feb 04, 2026Provide sterilely compounded pharmaceuticals from FDA-designated 503B facilities to support Gallup Indian Medical Center on an as-needed basis. Items include phenylephrine 100 mcg/mL, succinylcholine 20 mg/10 mL, LET 5 mL syringe, oxytocin 30 units in 500 mL (sterile-to-sterile and API), and epinephrine 8 mg per 250 mL bag (or other available strengths/volumes in IV bags). Products must be sterilely compounded in an FDA-approved 503B facility with a beyond-use date of at least 30 days from manufacture. The award will be a base period of one year with one option year, using multiple Blanket Purchase Agreements to maximize competition; additional capable vendors may be contacted if more BPAs are deemed in the government’s best interest. Capability statements, price lists, and catalogs from interested sources may be submitted for consideration.
This notice is a non-solicitation of quotations; no solicitation will be issued at this time. The two identified vendors are slated to hold the BPAs, with the possibility of additional awards only if the medical center’s needs change. Interested suppliers should submit capability statements, price lists, and catalogs via email by the stated deadline.
Notice of Intent to Award Multiple Blanket Purchase Agreements The Navajo Area Indian Health Service, Gallup Service Unit in Gallup, NM, intends to place multiple-award Blanket Purchase Agreements (BPA) with Fagron Compounding Services LLC (UEI: F7QNV46N18Q4) and American National Services LLC (UEI: LDNAY53JNV24) for sterilely compounded pharmaceuticals from an FDA-designated 503B facility on an as-needed basis. Items include Phenylephrine 100mcg.ml, Succinylcholine 20mg/10ml, LET 5ml syringe, Oxytoxin 30 units in 500ml (sterile to sterile and API), Epinephrine 8mg per 250ml bag (or other strength/volumes of the same medications in IV bags as available and required on an as-needed basis). Products must be sterilely compounded in an FDA approved facility with a beyond use date of at least 30 days from manufacture. The anticipated period of performance is a base period of one year from the date of award with one option period. The applicable North American Industry Classification System (NAICS) code assigned to this procurement is 325412- Pharmaceutical Preparation Manufacturing with a small business size standard of 1,300 employees. No further awards will be made unless the need for Gallup Indian Medical Center changes. The prospective, multiple-award BPAs as identified in this notice are sufficient at this time. In accordance with Part 12.201-1(e)(3)(i)(A), establishment of multiple BPAs constitute maximum practicable competition. Any other sources that believe they are capable of fulfilling the government requirements as described are encouraged to submit their capability statement, price lists, and catalogs to the point of contact listed below via email only and no later than 10:00AM (MST) on 2/18/2026. In the event additional BPAs are deemed to be in the best interest of the government, capable vendors may be contacted and be requested to establish a BPA with the Government. This notice of intent is not a request for quotations and a solicitation will not be issued.
From Special Notice posted on Feb 03, 2026Notice history
1Details
Award Information
Not yet awarded
Contacts
Agency
Place of Performance
USA